Insulin glargine: Difference between revisions
Created page with "{{Short description|Long-acting insulin}} {{Infobox drug | Verifiedfields = changed | verifiedrevid = 458271727 | image = Toujeo 300 IU-ml inj.jpg | width = | alt = | caption = Toujeo branded insulin glargine <!-- Clinical data --> | pronounce = | tradename = Lantus, Toujeo, Basaglar, others | Drugs.com = {{drugs.com|monograph|insulin_glargine}} | MedlinePlus = a600027 | DailyMedID = Insulin_glargine | pregn..." |
No edit summary |
||
| Line 1: | Line 1: | ||
<languages /> | |||
<translate> | |||
{{Short description|Long-acting insulin}} | {{Short description|Long-acting insulin}} | ||
{{Infobox drug | {{Infobox drug | ||
| Line 108: | Line 110: | ||
==Medical uses== | ==Medical uses== | ||
The long-acting insulin class, which includes insulin glargine, do not appear much better than [[NPH insulin|neutral protamine Hagedorn (NPH) insulin]], but do have a greater cost, making them, as of 2010, not cost effective for the treatment of type 2 diabetes. In a previous review it was unclear if there is a difference in [[hypoglycemia]], as there was not enough data to determine any differences with respect to long term outcomes, however a more recent [[Cochrane (organisation)|Cochrane]] [[systematic review]] did not find clinically significant difference when comparing insulin glargine to NPH insulin, [[insulin detemir]] or [[insulin degludec]] in the management of type I Diabetes in neither adults or children in periods of 6 months or longer. It is not typically the recommended long acting insulin in the United Kingdom. | The long-acting insulin class, which includes insulin glargine, do not appear much better than [[NPH insulin|neutral protamine Hagedorn (NPH) insulin]], but do have a greater cost, making them, as of 2010, not cost effective for the treatment of type 2 diabetes. In a previous review it was unclear if there is a difference in [[hypoglycemia]], as there was not enough data to determine any differences with respect to long term outcomes, however a more recent [[Cochrane (organisation)|Cochrane]] [[systematic review]] did not find clinically significant difference when comparing insulin glargine to NPH insulin, [[insulin detemir]] or [[insulin degludec]] in the management of type I Diabetes in neither adults or children in periods of 6 months or longer. It is not typically the recommended long acting insulin in the United Kingdom. | ||
| Line 167: | Line 168: | ||
[[Category:Sanofi]] | [[Category:Sanofi]] | ||
[[Category:World Health Organization essential medicines]] | [[Category:World Health Organization essential medicines]] | ||
</translate> | |||